Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.6% - Here's Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares fell 1.6% during mid-day trading on Tuesday . The stock traded as low as $5.72 and last traded at $5.75. 2,857,604 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 12,252,407 shares. The stock had previously closed at $5.84.

Wall Street Analysts Forecast Growth

RXRX has been the topic of a number of recent research reports. Needham & Company LLC restated a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. KeyCorp decreased their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners decreased their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Finally, Morgan Stanley dropped their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of "Hold" and an average target price of $8.20.

Recursion Pharmaceuticals Stock Performance

The firm has a fifty day simple moving average of $6.11 and a 200-day simple moving average of $6.78. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a market cap of $2.35 billion, a PE ratio of -3.81 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analysts' expectations of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company's quarterly revenue was down 57.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.42) EPS. On average, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Large investors have recently bought and sold shares of the business. Decker Retirement Planning Inc. acquired a new position in Recursion Pharmaceuticals in the 4th quarter valued at about $26,000. Private Trust Co. NA acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $27,000. GAMMA Investing LLC raised its stake in shares of Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares during the period. Finally, NewEdge Advisors LLC grew its position in Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after buying an additional 2,387 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.